1. Generics Bulletin
  2. >>Business
  3. >>Deals

Ipca Launches Bid To Buy A Third Of Unichem, Eyes Majority Ownership

Initial 33% Acquisition Could Be Bolstered By Additional 26% Stake

 
• By Dean Rudge

API and formulations firm Ipca Laboratories is to spend more than INR10bn to acquire a 33% holding in its fellow Indian firm Unichem Laboratories, with designs to add a further 26% stake.

M&A
• Source: khwanchai phanthong/Alamy Stock Photo (khwanchai phanthong / Alamy Stoc/Alamy Stock Photo)

Ipca Laboratories has reached a definitive agreement to acquire a 33.38% stake in its fellow Indian firm Unichem Laboratories for INR10.34bn ($126.2m) in cash, in what Ipca believes is a complementary transaction that aligns with its strategy “to enhance our portfolio in our chosen growth markets.”

At the same time, Ipca is launching an open offer of INR8

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.